Literature DB >> 19909382

Age-related plasma reference ranges for two heparin-binding proteins--vitronectin and platelet factor 4.

F Newall1, L Johnston, V Ignjatovic, R Summerhayes, P Monagle.   

Abstract

This study was conducted to establish age-related reference ranges for two heparin-binding proteins--vitronectin and platelet factor 4 (PF4)--and to determine if the quantitative values of these proteins may contribute to the reported age-dependent effect of unfractionated heparin (UFH). Plasma samples were obtained from healthy children aged between 1 month and 16 years and from healthy adult volunteers. Two commercial kits were used to measure plasma vitronectin and PF4 levels. Results were reported as mean and boundaries including 95% of the population. Plasma vitronectin levels for children aged 1-5 years were significantly higher compared with adults. Plasma PF4 levels for infants <1 year of age were significantly lower compared with adults. The differences between reference values for both proteins in all other age-groups were not statistically significant. This study for the first time has established age-related reference ranges for vitronectin and PF4. In establishing these ranges, the quantitative values of these proteins do not appear to be the major contributory cause for the age-dependent variation in UFH effect. Future studies are required to evaluate the possible impact of age-dependent differences in binding between heparin-binding proteins and UFH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909382     DOI: 10.1111/j.1751-553X.2008.01107.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  8 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Serum vitronectin levels in patients with Behçet's disease.

Authors:  Ali Yalçındağ; Aslıhan Uzun; F Nilüfer Yalçındağ; Namık Delibaş
Journal:  Inflamm Res       Date:  2012-07-19       Impact factor: 4.575

3.  Discovery and characterization of potential prognostic biomarkers for dengue hemorrhagic fever.

Authors:  B Katherine Poole-Smith; Alexa Gilbert; Andrea L Gonzalez; Manuela Beltran; Kay M Tomashek; Brian J Ward; Elizabeth A Hunsperger; Momar Ndao
Journal:  Am J Trop Med Hyg       Date:  2014-10-27       Impact factor: 2.345

4.  Activity of MMP-19 inhibits capillary-like formation due to processing of nidogen-1.

Authors:  B Titz; S Dietrich; T Sadowski; C Beck; A Petersen; R Sedlacek
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

5.  Prognostic utility of serum vitronectin levels in acute myocardial infarction.

Authors:  S Aslan; B Ikitimur; H A Cakmak; B Karadag; E Y Tufekcioglu; H Ekmekci; H Yuksel
Journal:  Herz       Date:  2014-05-15       Impact factor: 1.443

6.  Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis.

Authors:  Kandace Gollomp; Amrita Sarkar; Sanjiv Harikumar; Steven H Seeholzer; Gowthami M Arepally; Kristin Hudock; Lubica Rauova; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2020-03-05       Impact factor: 25.476

Review 7.  Glycosaminoglycan Neutralization in Coagulation Control.

Authors:  Amélie I S Sobczak; Samantha J Pitt; Alan J Stewart
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-19       Impact factor: 8.311

Review 8.  Anticoagulant therapy in pediatrics.

Authors:  Mariam K Dabbous; Fouad R Sakr; Diana N Malaeb
Journal:  J Basic Clin Pharm       Date:  2014-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.